Decheng Capital — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)
Board seatMin Cui· per SEC Form D
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDentsu VenturesFelicis Ventures+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.